Harrow (HROW) Analyst Targets Signal +129% Upside to $63

Key Takeaways

• The central price target of $63 is the arithmetic mean of eight verified analyst price targets collected from reputable sources, spanning a wide range of roughly $45 to $88.
• Shares of HROW closed near $27.50, meaning reaching $63 would require roughly 129% upside — a very large move by any conventional measure.
• All reviewed ratings are Buy or Overweight, but several firms have trimmed their targets as the stock slid from its $54.85 52-week high, signaling a cautious recalibration despite the bullish tilt.
• The strongest supporting factors are revenue expansion in the branded ophthalmic franchise and a diversified eyecare portfolio, while persistent GAAP losses and a downward-shifting target range are the biggest risks.
• For more on HROW's Major News and Today's Price Move, plus its Forecast and Earnings, explore these dedicated pages.
• To see how AI-driven strategies are positioning across the market, explore Trending AI Robots.

Analyst Consensus and Price Targets

Harrow, Inc. (HROW) — formerly Harrow Health, Inc., a Nashville-based eyecare pharmaceutical company — carries a "Strong Buy" tilt from Wall Street, but the individual targets tell a more nuanced story. The verified targets reviewed include $45 (Zacks Research), $59 (Craig-Hallum), $60 (Lake Street), $60 (B. Riley Securities), $62 (Ladenburg Thalmann), $63 (BTIG), $70 (H.C. Wainwright), and $88 (Cantor Fitzgerald). The arithmetic mean of these eight figures is approximately $63, which serves as the central target for this analysis.

The low-to-high range of about $45 to $88 is unusually wide, reflecting genuine disagreement over the company's growth trajectory. Recent actions have leaned defensive: B. Riley lowered its target from $65 to $60, Ladenburg trimmed $66 to $62, and Cantor Fitzgerald cut $91 to $88. The $45 figure from a newer initiation underscores how far expectations have reset after the stock's sharp decline from its January 2026 high near $55. No analyst view here should be read as a guarantee that $63 will be reached.

Current Position and the Road to the Target

HROW closed near $27.50 in recent trading, placing it far below its 52-week high of $54.85 and just above its 52-week low near $25.76. Reaching the $63 central target therefore requires roughly a 129% advance — a very large move that would demand not just a recovery but a substantial re-rating of the business. The company generates trailing-twelve-month revenue in the mid-$200-million range but remains GAAP unprofitable, reporting a net loss in its most recent June-quarter results on about $70 million in revenue. For the stock to travel toward $63, investors would likely need to see sustained revenue acceleration, a credible path to profitability, and renewed confidence that the valuation can support a much higher price.

Factors That Could Support a Move Toward the Target

Harrow operates two complementary segments: a Branded business built around FDA-approved ophthalmic products and the ImprimisRx compounding platform, which together give it exposure across the U.S. eyecare market. Revenue has expanded year over year in recent quarters, and analysts generally cite the growing ophthalmic franchise and a long-term product pipeline as reasons for their Buy ratings. A return toward prior highs would likely require accelerating demand for its branded treatments, improved gross margins, and evidence that operating losses are narrowing. Favorable sector conditions for specialty pharma and a rebound in investor sentiment toward small-cap healthcare names could also provide a tailwind. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

Risks That Could Hold Back the Target

The most significant obstacle is profitability. HROW continues to post GAAP losses, and its negative EPS (earnings per share) leaves traditional valuation metrics such as P/E (price-to-earnings) of limited use, forcing investors to rely on revenue multiples that can compress quickly. The stock's steep fall from $55 to the mid-$20s reflects waning confidence, and recent insider selling has added to the overhang. A wide and downward-drifting target range, valuation compression, slower demand growth, competitive pressure in ophthalmology, and broader macroeconomic or rate-driven weakness in small-cap healthcare are all factors that could keep the stock well below $63.

Technical Levels and Market Structure

HROW is trading near the bottom of its 52-week range after a prolonged downtrend. The area around $25.76 to $26 represents a key support zone, while prior breakdown levels near $28 to $30 could act as initial resistance on any rebound. The $54.85 52-week high is a distant overhead reference that underscores the magnitude of the recovery implied by the central target. The stock would need to reclaim and hold levels well above its recent consolidation before a move toward $63 could even begin to take shape.

Time Horizon and What Investors Should Monitor

Analyst price targets generally reflect a research horizon of roughly 12 months, though individual firms differ and no horizon should be assumed for every report. The most important upcoming items are quarterly earnings and guidance, changes in revenue growth and loss trends, and any analyst target revisions — particularly whether firms continue lowering targets toward the current price or begin lifting them again. Investors should also watch insider activity, ophthalmic product launches and demand, and broader conditions for small-cap healthcare, including interest-rate expectations and sector fund flows.

Using AI Daily Buy/Sell Signals in Research

In my own process, I often review Tickeron’s AI Daily Buy/Sell Signals to monitor momentum shifts across volatile names like this one. These tools apply artificial intelligence to scan thousands of stocks and ETFs, producing Buy, Sell, or Hold signals based on technical behavior and market conditions. Pairing that layer with fundamental work can help surface potential changes in trend earlier than manual review alone.

Final Assessment

The $63 central target for HROW is a calculated average of eight verified analyst price targets spanning roughly $45 to $88 — not an official published consensus. From a recent close near $27.50, reaching that level would require a very large advance of about 129%. The bullish case rests on an expanding ophthalmic franchise and revenue growth, while the bearish case centers on persistent GAAP losses, valuation compression, and a target range that has been drifting lower. The wide spread between the lowest and highest targets signals genuine uncertainty about the pace of any recovery. Whether HROW can reach $63 depends primarily on sustained revenue acceleration, a credible path to profitability, and a durable shift in market sentiment — none of which can be predicted with confidence.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Contributor

Sergey Savastiouk|Expert

Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.

Notable companies

Industry description

Market Cap

High and low price notable news

Volume